Arlene Gayle, MD

Overview

Arlene Gayle, MD is a board-certified hematology oncology physician. After receiving her medical degree at the University of West Indies in Kingston, Jamaica, she completed a residency at Newark Beth Israel Medical Center in Newark, New Jersey. In addition, Dr. Gayle completed fellowships in hematology, oncology, and geriatric medicine at the University of Wisconsin in Madison. A skilled and experienced practitioner, Dr. Gayle was the Medical Director of the Marshfield Clinic Health System FACT accredited stem cell transplant program in Marshfield, Wisconsin and Chief of Staff at Flambeau Hospital in Park Falls, Wisconsin. She is also an inspector for Foundation for the Accreditation of Cellular Therapy (FACT). Her practice is focused on blood and marrow transplants for adult patients.

Articles

Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes

BLOOD

2022

Caregiver-Oncologist Prognostic Concordance, Caregiver Mastery, and Caregiver Psychological Health and Quality of Life

The oncologist

2021

Unexpected doxorubicin-mediated cardiotoxicity in sisters: possible role of polymorphisms in histamine n-methyl transferase.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

2013

Increasing disparity in colorectal cancer incidence and mortality among African Americans and whites: A state's experience

JOURNAL OF GASTROINTESTINAL ONCOLOGY

2011

Associated Clinical Trials

NCT04245397

A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy

This study is currently enrolling.

This research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.

NCT04998747

A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)

$Icon for trial | 20200446 A Phase 1b Open-label Study Evaluating the Safety and Pharmacokinetics of Subcutaneous AMG 701 for the Treatment of Relapsed or Refractory Multiple Myeloma (ProxiMMity-1)$

Participants who have have relapsed (returning) and refractory (stopped responding to treatment) multiple myeloma (RRMM) will be invited to take part in this study. This study is being done to learn more about the drug AMG 701 ...

NCT05346835

68284528MMY4006 EAP: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-cel) Out-of-Specification (OOS) in Patients With Multiple Myeloma